PRJNA286122
NOVEL ADOPTIVE IMMUNOTHERAPY APPROACH THROUGH MIHA TARGETING
Personalized anti-cancer treatment based on our proprietary geno-proteomic approach that hinges on a combination of next generation sequencing and high-throughput mass spectrometry (MS) peptide identification.